Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 409306 in Attenuated Psychosis Syndrome
CTR20192418Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osoresnontrine in attenuated psychosis syndrome (APS), sponsored by Boehringer Ingelheim. Started Nov 2019; status: completed.
02
Drugs
osoresnontrine
03
Conditions
attenuated psychosis syndrome (APS)
Beyond the preview
Go deeper on CTR20192418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192418.